Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
NCT06234605
Recruiting
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: University of Arizona Cancer Center, Tucson, Arizona
Conditions: Renal Cell Carcinoma
Register for Updates
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02199665
Recruiting
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blockin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Mayo Clinic (AZ), Scottsdale, Arizona
Conditions: Refractory Multiple Myeloma
Register for Updates
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: Lenzmeier Family Medicine/CCT Research, Glendale, Arizona
Conditions: Lower Respiratory Tract Illness
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Honor Health, Phoenix, Arizona
Conditions: Uterine Serous Carcinoma
Register for Updates
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT04683315
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: HonorHealth Medical Group, Scottsdale, Arizona
Conditions: Pancreatic Cancer
Register for Updates
Pompe Pregnancy Sub-Registry
NCT00567073
Recruiting
This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standa... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
11/19/2024
Locations: Barrow Neurol Group- Site Number : 840087, Phoenix, Arizona
Conditions: Glycogen Storage Disease Type II (GSD-II), Pompe Disease (Late-onset), Glycogenesis 2 Acid Maltase Deficiency
Register for Updates
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Phoenix Children's Hospital- Site Number : 840003, Phoenix, Arizona
Conditions: Mucopolysaccharidosis I (MPS I)
Register for Updates
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
NCT06398626
Recruiting
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod. All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according t... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/18/2024
Locations: Reddy GI Associates, Mesa, Arizona
Conditions: Colitis, Ulcerative
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: Banner Alzheimer's Institute, Phoenix, Arizona
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates
Combining a Smartphone App With Medications to Manage Heavy Drinking
NCT06303778
Recruiting
One in 10 Veterans have an alcohol use disorder. However, few Veterans receive evidenced-based psychosocial interventions or medications to treat alcohol use disorder. Barriers to receiving these treatments include long wait times, stigma, and long distances from treatment facilities. Even fewer Veterans receive psychosocial and medication interventions together, despite clinical practice guidelines recommending both and evidence of better outcomes. Expanding access to these treatments in primar... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/15/2024
Locations: Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT04794699
Recruiting
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona
Conditions: Solid Tumor
Register for Updates
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
NCT06160206
Recruiting
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a period of improvement (recurrent). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as retifanlimab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Register for Updates